Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.
Sanofi reported that its investigational drug efdoralprin alfa showed clear superiority to standard-of-care therapy in a phase 2 trial for AATD-related emphysema.
The phase 2 ElevAATe study found higher and more consistent functional AAT levels, with less frequent dosing and a similar safety profile versus current plasma-derived treatments.
The company plans to engage with regulators on next steps for the recombinant therapy, which holds fast track and orphan designations in the US and EU.
For investors tracking ENXTPA:SAN, this update adds a fresh clinical asset to the wider story at a time when the stock is trading around €76.67. The share price is up 5.4% over the past week but down 6.5% over the past month and down 6.9% year to date, with a decline of 13.6% over the past year and a more modest gain of 7.1% over five years.
With efdoralprin alfa progressing on the back of phase 2 data, attention now turns to the scope and timing of regulatory discussions and any future late-stage trial plans. Investors will likely watch how Sanofi positions this potential therapy in the rare respiratory disease space and how it fits into the company’s broader pipeline ambitions.
Stay updated on the most important news stories for Sanofi by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Sanofi.
ENXTPA:SAN Earnings & Revenue Growth as at May 2026
4 things going right for Sanofi that this headline doesn’t cover.
Efdoralprin alfa gives Sanofi a differentiated angle in alpha-1 antitrypsin deficiency, where current care has relied on weekly plasma-derived infusions since the late 1980s. The phase 2 ElevAATe data point to higher and more consistent functional AAT levels with dosing every three or four weeks, while reporting a broadly comparable safety profile to plasma therapy in this trial. For you as an investor, that combination of efficacy signals and convenience is important because it speaks directly to how a future product could be positioned on both clinical and patient-experience grounds in a rare disease market of roughly 235,000 people worldwide, many of whom are currently undiagnosed. Fast track and orphan designations in the US and EU add regulatory support, although efdoralprin alfa remains in development and has not been reviewed by regulators. The key questions now sit around how regulators view the phase 2 package, what a potential phase 3 program might look like, and how this recombinant therapy could be priced and reimbursed against plasma-derived competitors such as CSL and Grifols in a niche but specialized respiratory segment.
How This Fits Into The Sanofi Narrative
This rare-disease respiratory asset lines up with the narrative theme that Sanofi is leaning into high-value biologics and specialty indications as part of its long-term growth story.
The mixed late-stage experience elsewhere in the respiratory pipeline, such as itepekimab in COPD, means investors may treat efdoralprin alfa as a test of whether pipeline execution can match the narrative.
The broader community narrative focuses heavily on immunology, vaccines and major launches like Dupixent, so AATD-related emphysema may not yet be fully reflected in how investors frame Sanofi’s future product mix.
Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Sanofi to help decide what it’s worth to you.
The Risks and Rewards Investors Should Consider
⚠️ Phase 2 success does not guarantee regulatory approval or commercial uptake, and a larger, longer phase 3 program could still reveal safety or efficacy issues.
⚠️ Rare-disease therapies often depend on complex pricing and reimbursement decisions, so payer pushback could limit the commercial potential even with strong functional AAT data.
🎁 Sanofi is adding another recombinant biologic to its respiratory and rare-disease portfolio, which can support its positioning alongside large-cap peers such as AstraZeneca and GSK in specialty care.
🎁 Less frequent dosing than weekly plasma therapy, combined with higher functional AAT levels in this trial, could support differentiated product positioning if future studies and regulators align.
What To Watch Going Forward
From here, focus on how Sanofi describes its regulatory interactions for efdoralprin alfa, any details it provides on a potential phase 3 design, and whether longer-term safety and efficacy data from the ongoing extension study are consistent with the ElevAATe readout. It is also worth tracking commentary at upcoming conferences on how management prioritizes this asset versus other late-stage programs, and how AATD fits into the overall rare-disease and respiratory strategy next to therapies from competitors such as CSL, Grifols and AstraZeneca.
To ensure you’re always in the loop on how the latest news impacts the investment narrative for Sanofi, head to the community page for Sanofi to never miss an update on the top community narratives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SAN.PA.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com